Esperion Therapeutics (NASDAQ:ESPR) Earns Sell (D-) Rating from Weiss Ratings

Key Points

• Weiss Ratings reissued a "sell (D-)" rating for Esperion Therapeutics, reflecting negative outlook on the company's stock performance.
• Esperion Therapeutics reported a quarterly revenue of $82.39 million, significantly exceeding analysts' expectations of $62.55 million.
• Institutional investors own approximately 47.39% of Esperion's shares, indicating significant interest from large investment firms.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report)'s stock had its "sell (d-)" rating reissued by research analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Other analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a "buy" rating and set a $16.00 target price on shares of Esperion Therapeutics in a report on Friday, September 19th. Wall Street Zen raised shares of Esperion Therapeutics from a "hold" rating to a "buy" rating in a report on Friday, September 26th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $7.00.

Esperion Therapeutics Price Performance

Shares of ESPR opened at $2.57 on Wednesday. The firm has a 50-day moving average of $2.35 and a 200-day moving average of $1.53. Esperion Therapeutics has a one year low of $0.69 and a one year high of $3.94. The company has a market cap of $518.16 million, a PE ratio of -5.24, a price-to-earnings-growth ratio of 52.06 and a beta of 0.96.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.15. The firm had revenue of $82.39 million during the quarter, compared to the consensus estimate of $62.55 million. Analysts expect that Esperion Therapeutics will post -0.29 earnings per share for the current year.

Institutional Trading of Esperion Therapeutics

A number of institutional investors have recently bought and sold shares of ESPR. Synergy Asset Management LLC boosted its holdings in Esperion Therapeutics by 3,496.3% in the 1st quarter. Synergy Asset Management LLC now owns 31,000 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 30,138 shares during the period. Summit Wealth Group LLC boosted its holdings in Esperion Therapeutics by 86.6% in the 1st quarter. Summit Wealth Group LLC now owns 293,000 shares of the biopharmaceutical company's stock valued at $422,000 after purchasing an additional 136,000 shares during the period. Private Advisor Group LLC boosted its holdings in Esperion Therapeutics by 33.2% in the 1st quarter. Private Advisor Group LLC now owns 40,106 shares of the biopharmaceutical company's stock valued at $58,000 after purchasing an additional 10,000 shares during the period. Foundations Investment Advisors LLC boosted its holdings in Esperion Therapeutics by 66.3% in the 1st quarter. Foundations Investment Advisors LLC now owns 50,172 shares of the biopharmaceutical company's stock valued at $72,000 after purchasing an additional 20,000 shares during the period. Finally, SLT Holdings LLC raised its position in shares of Esperion Therapeutics by 66.7% in the 1st quarter. SLT Holdings LLC now owns 50,000 shares of the biopharmaceutical company's stock valued at $72,000 after buying an additional 20,000 shares in the last quarter. Institutional investors own 47.39% of the company's stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.